Sagimet Biosciences Inc. (SGMT)
| Market Cap | 435.97M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -43.51M |
| Shares Out | 61.75M |
| EPS (ttm) | -1.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,602,404 |
| Open | 6.85 |
| Previous Close | 6.86 |
| Day's Range | 6.80 - 7.15 |
| 52-Week Range | 4.50 - 11.41 |
| Beta | 3.44 |
| Analysts | Strong Buy |
| Price Target | 26.20 (+271.11%) |
| Earnings Date | Aug 12, 2026 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for SGMT stock is "Strong Buy." The 12-month stock price target is $26.2, which is an increase of 271.11% from the latest price.
News
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic...
Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH
Phase 1 clinical data poster selected as a Best of EASL 2026 presentation Combination of denifanstat and resmetirom was generally well-tolerated in Phase 1 clinical trial Phase 1 data show rapid reduc...
Sagimet Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Enhanced focus on dermatology leverages FASN inhibitors for moderate to severe acne, with denifanstat showing strong efficacy and safety in Chinese trials. U.S. phase III will include adolescents, and pipeline expansion includes a more potent molecule and topical formulations targeting broader acne populations.
Sagimet Biosciences price target lowered to $12 from $35 at Citizens
Citizens lowered the firm’s price target on Sagimet Biosciences (SGMT) to $12 from $35 and keeps an Outperform rating on the shares. Sagimet Biosciences is advancing denifanstat into a Phase…
Sagimet Biosciences price target lowered to $28 from $37 at Clear Street
Clear Street lowered the firm’s price target on Sagimet Biosciences (SGMT) to $28 from $37 and keeps a Buy rating on the shares. The firm is adjusting its model following…
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic ...
Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)
“Our recent strategic decision to focus on dermatology marks a turning point for Sagimet, and we are excited about the path ahead. In the near term, we are targeting the…
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Secured equity financing with gross proceeds of $175M in April 2026 Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 Fi...
Sagimet Biosciences Quarterly report: Q1 2026
Sagimet Biosciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
Sagimet Biosciences Earnings release: Q1 2026
Sagimet Biosciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Pre-clinical data shows potential for FASN inhibition as mechanism of action to treat acne Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate i...
Sagimet Biosciences price target raised to $49 from $28 at Canaccord
Canaccord raised the firm’s price target on Sagimet Biosciences (SGMT) to $49 from $28 and keeps a Buy rating on the shares. The firm noted the company announced the re-prioritization…
Sagimet Biosciences price target raised to $33 from $28 at Oppenheimer
Oppenheimer raised the firm’s price target on Sagimet Biosciences (SGMT) to $33 from $28 and keeps an Outperform rating on the shares. The firm notes the company hosted Dr. Julie…
Sagimet Biosciences Transcript: Status update
Denifanstat, a novel oral FASN inhibitor, is advancing to a U.S. phase III trial for moderate to severe acne after strong efficacy and safety results in China. The company is also developing a second oral and a topical FASN inhibitor, with a robust cash position supporting operations through 2028.
Sagimet Biosciences Slides: Status update
Sagimet Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on April 30, 2026.
Sagimet Biosciences management to meet virtually with Clear Street
Virtual Meeting to be held on May 4 hosted by Clear Street.
Sagimet Biosciences price target lowered to $25 from $27 at Guggenheim
Guggenheim lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $27 and keeps a Buy rating on the shares. The firm is “enthusiastically supportive” of Sagimet’s strategic…
3 Penny Stocks to Watch Now, 4/28/26
High-Trend International Group ($HTCO), Youxin Technology Limited ($YAAS), and Sagimet Biosciences ($SGMT) are the three penny stocks to watch on April 28, according to TipRanks’ Penny Stock Screener ...
Sagimet Biosciences holds a conference call
Conference call with Julie Harper who will provide details on the acne program to be held on April 30 at 2 pm hosted by Sagimet Biosciences (SGMT). Published first on…
TD Cowen establishes $21 price target for Sagamet Bioscinces
TD Cowen analyst Ritu Baral established a $21 price target for Sagimet Biosciences (SGMT) and maintained its Buy rating. The target was established after the company announced it will prioritize…
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli...
Sagimet Biosciences Provides Strategic and Corporate Updates
Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. planned to initiate in second half of 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongo...
Sagimet Biosciences Proxy statement: Proxy filing
Sagimet Biosciences filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
Sagimet Biosciences appoints Grauer as Chief Medical Officer
Sagimet Biosciences (SGMT) announced the appointment of Andreas Grauer, MD, as Chief Medical Officer, effective April 20, 2026. Sagimet’s prior Chief Medical Officer, Eduardo Bruno Martins, MD, DPhil,...
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
SAN MATEO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metaboli...